Gensight Biologics (XPAR:SIGHT) Effective Interest Rate on Debt % : 20.99% (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Gensight Biologics Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Gensight Biologics's annualized positive value of Interest Expense for the quarter that ended in Dec. 2023 was €3.62 Mil. Gensight Biologics's average total debt for the quarter that ended in Dec. 2023 was €17.23 Mil. Therefore, Gensight Biologics's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 was 20.99%.

Gensight Biologics Effective Interest Rate on Debt % Historical Data

The historical data trend for Gensight Biologics's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gensight Biologics Effective Interest Rate on Debt % Chart

Gensight Biologics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Effective Interest Rate on Debt %

Get a 7-Day Free Trial

5.65

15.86

16.03

21.02

20.29

Gensight Biologics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Effective Interest Rate on Debt %	Get a 7-Day Free Trial															15.85	15.79	29.06	18.73	20.99

Competitive Comparison of Gensight Biologics's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Gensight Biologics's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gensight Biologics's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gensight Biologics's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Gensight Biologics's Effective Interest Rate on Debt % falls into.

Gensight Biologics Effective Interest Rate on Debt % Calculation

Gensight Biologics's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (A: Dec. 2022 )	+	Total Debt (A: Dec. 2023 ))	/ count )
=	-1 * -3.152	/	( (12.647	+	18.428)	/ 2 )
=	-1 * -3.152	/	15.5375
=	20.29 %

where

	Total Debt (A: Dec. 2022 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	10.218	+	2.429
=	12.647

	Total Debt (A: Dec. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	1.048	+	17.38
=	18.428

Gensight Biologics's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (Q: Jun. 2023 )	+	Total Debt (Q: Dec. 2023 ))	/ count )
=	-1 * -3.618	/	( (16.04	+	18.428)	/ 2 )
=	-1 * -3.618	/	17.234
=	20.99 %

where

	Total Debt (Q: Jun. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0.644	+	15.396
=	16.04

	Total Debt (Q: Dec. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	1.048	+	17.38
=	18.428

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is two times the semi-annual (Dec. 2023) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

Gensight Biologics (XPAR:SIGHT) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

Gensight Biologics Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Gensight Biologics's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.

Gensight Biologics (XPAR:SIGHT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gensight Biologics SA (XPAR:SIGHT) » Definitions » Effective Interest Rate on Debt %

Comparable Companies

Traded in Other Exchanges

GSGTF:USA G49N:Germany

Address

74,rue du Faubourg Saint-Antoine, Paris, FRA, 75012

Website

https://www.gensight-biologics.com

Gensight Biologics SA is a clinical-stage biotechnology group discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence, and Optogenetics, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. The group focus is on ophthalmology where it develops product candidates to restore eyesight to patients suffering from retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.

Gensight Biologics (XPAR:SIGHT) Headlines

No Headlines